great posts , page-3

Garry & Roblun,

It will happen.

As has been said a number of times, the company is not interested in day-to-day SP gyrations or the interests of short term holders.

Frustrating, I know, but you can be assured that when announcements are made (as with the SiYi JV announcement last December) they will be substantial and not 'works-in-progress' or 'pipe dreams'.

I don't think there will be one 'knock out punch'. Instead, there will be a series of major announcements which, collectively, will see the company well and truly 'made'. These will happen over the next 3-4 months, starting any day.

Here's the list of breakthrough's as I see them (and recently posted) through to the end of year.

In terms of news and/or announcements, this is what we are likely in for over the next 4 months. Many of these will be accompanied by announcements:


SEPTEMBER

1. Mexico import license approval

2. Oraline order for Nuevo Leon schools testing

3. Final approvals for sales of Oraline by Top Med in Poland

4. Significant orders in Russia (perhaps including the Latvian roadside testing)


OCTOBER

1. MPS approval of Oraline and commencement of field testing in 15 cities

2. Results of Probeline trials

3. Commencement of drug testing in Nuevo Leon schools

4. Sept Qtr results and Investor Update


NOVEMBER

1. Launch of Oraline 8 at the Medica Conference (18-22 November)


DECEMBER - JAN

1. Relaunch of Visualine (with 2 additional drugs and lower price point)

2. Launch of Bioscreens split cup

3. UK distributorship agreement(s)

4. Completion of Chinese field trials and commencement of production/sales


Other possible news items, but which can’t be time estimated, include CMM’s progress with identifying required changes to Oraline to comply with Australian Standards in workplace testing and possible increases in US and other distributorships.